IL130065A - Gel preparations for local administration of drugs - Google Patents

Gel preparations for local administration of drugs

Info

Publication number: IL130065A
Authority: IL; Israel
Prior art keywords: formulation; ethanol; ethoxymethyl; amino; percent
Prior art date: 1996-12-03

Application number

IL13006597A

Other languages

English (en)

Hebrew (he)

Other versions

IL130065A0 (en

Original Assignee

Minnesota Mining & Mfg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-12-03

Filing date

1997-12-01

Publication date

2004-06-20

1997-12-01 Application filed by Minnesota Mining & Mfg filed Critical Minnesota Mining & Mfg

2000-02-29 Publication of IL130065A0 publication Critical patent/IL130065A0/xx

2004-06-20 Publication of IL130065A publication Critical patent/IL130065A/en

Links

239000000203 mixture Substances 0.000 title claims abstract description 81
238000009472 formulation Methods 0.000 title claims abstract description 75
230000000699 topical effect Effects 0.000 title description 6
238000012377 drug delivery Methods 0.000 title description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 57
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims abstract description 47
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 28
229940075614 colloidal silicon dioxide Drugs 0.000 claims abstract description 24
235000013773 glyceryl triacetate Nutrition 0.000 claims abstract description 23
239000001087 glyceryl triacetate Substances 0.000 claims abstract description 23
229960002622 triacetin Drugs 0.000 claims abstract description 23
235000013772 propylene glycol Nutrition 0.000 claims abstract description 19
LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
238000011200 topical administration Methods 0.000 claims 2
230000003287 optical effect Effects 0.000 abstract 1
239000000499 gel Substances 0.000 description 35
210000004027 cell Anatomy 0.000 description 20
229940079593 drug Drugs 0.000 description 20
239000003814 drug Substances 0.000 description 20
239000012530 fluid Substances 0.000 description 17
102000014150 Interferons Human genes 0.000 description 14
108010050904 Interferons Proteins 0.000 description 14
102000004127 Cytokines Human genes 0.000 description 13
108090000695 Cytokines Proteins 0.000 description 13
229940079322 interferon Drugs 0.000 description 13
108060008682 Tumor Necrosis Factor Proteins 0.000 description 11
238000000034 method Methods 0.000 description 11
238000010998 test method Methods 0.000 description 11
102000003390 tumor necrosis factor Human genes 0.000 description 11
230000006698 induction Effects 0.000 description 10
238000009792 diffusion process Methods 0.000 description 9
210000004379 membrane Anatomy 0.000 description 9
239000012528 membrane Substances 0.000 description 9
150000001875 compounds Chemical class 0.000 description 8
241000699670 Mus sp. Species 0.000 description 6
201000010099 disease Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 5
238000003756 stirring Methods 0.000 description 5
230000001186 cumulative effect Effects 0.000 description 4
239000011521 glass Substances 0.000 description 4
230000035515 penetration Effects 0.000 description 4
238000005070 sampling Methods 0.000 description 4
239000000243 solution Substances 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
206010059313 Anogenital warts Diseases 0.000 description 3
208000000907 Condylomata Acuminata Diseases 0.000 description 3
208000009889 Herpes Simplex Diseases 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
208000025009 anogenital human papillomavirus infection Diseases 0.000 description 3
201000004201 anogenital venereal wart Diseases 0.000 description 3
238000004166 bioassay Methods 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
229910002016 Aerosil® 200 Inorganic materials 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
241000710188 Encephalomyocarditis virus Species 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
241000700159 Rattus Species 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
230000036760 body temperature Effects 0.000 description 2
210000005056 cell body Anatomy 0.000 description 2
230000000120 cytopathologic effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
210000004400 mucous membrane Anatomy 0.000 description 2
230000000149 penetrating effect Effects 0.000 description 2
239000008252 pharmaceutical gel Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
239000000902 placebo Substances 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000007974 sodium acetate buffer Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000012385 systemic delivery Methods 0.000 description 2
239000012049 topical pharmaceutical composition Substances 0.000 description 2
238000012384 transportation and delivery Methods 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
229910002012 Aerosil® Inorganic materials 0.000 description 1
239000004254 Ammonium phosphate Substances 0.000 description 1
206010004146 Basal cell carcinoma Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
206010008263 Cervical dysplasia Diseases 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
102000004890 Interleukin-8 Human genes 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
208000000260 Warts Diseases 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
208000009621 actinic keratosis Diseases 0.000 description 1
229910000148 ammonium phosphate Inorganic materials 0.000 description 1
235000019289 ammonium phosphates Nutrition 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
229960004756 ethanol Drugs 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940096397 interleukin-8 Drugs 0.000 description 1
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
230000007794 irritation Effects 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
238000005065 mining Methods 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
230000009854 mucosal lesion Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000002245 particle Substances 0.000 description 1
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
239000008250 pharmaceutical cream Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
-1 polyethylene Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
OJTDGPLHRSZIAV-UHFFFAOYSA-N propane-1,2-diol Chemical compound CC(O)CO.CC(O)CO OJTDGPLHRSZIAV-UHFFFAOYSA-N 0.000 description 1
BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
201000010153 skin papilloma Diseases 0.000 description 1
238000002943 spectrophotometric absorbance Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000008719 thickening Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
229940042129 topical gel Drugs 0.000 description 1
229940086542 triethylamine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Dermatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Inorganic Chemistry (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IL13006597A 1996-12-03 1997-12-01 Gel preparations for local administration of drugs IL130065A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/759,992 US5939090A (en)	1996-12-03	1996-12-03	Gel formulations for topical drug delivery
PCT/US1997/021995 WO1998024436A2 (fr)	1996-12-03	1997-12-01	Formulations sous forme de gel pour l'administration locale de medicaments

Publications (2)

Publication Number	Publication Date
IL130065A0 IL130065A0 (en)	2000-02-29
IL130065A true IL130065A (en)	2004-06-20

Family

ID=25057713

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL13006597A IL130065A (en)	1996-12-03	1997-12-01	Gel preparations for local administration of drugs

Country Status (18)

Country	Link
US (2)	US5939090A (fr)
EP (1)	EP0942724B1 (fr)
JP (1)	JP4615633B2 (fr)
KR (1)	KR100503716B1 (fr)
AT (1)	ATE245422T1 (fr)
AU (1)	AU723897B2 (fr)
BR (1)	BR9713677B1 (fr)
CA (1)	CA2273094C (fr)
CZ (1)	CZ301713B6 (fr)
DE (1)	DE69723721T2 (fr)
DK (1)	DK0942724T3 (fr)
ES (1)	ES2200206T3 (fr)
HU (1)	HU229599B1 (fr)
IL (1)	IL130065A (fr)
NO (1)	NO325684B1 (fr)
NZ (1)	NZ335821A (fr)
PT (1)	PT942724E (fr)
WO (1)	WO1998024436A2 (fr)

Families Citing this family (165)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5741908A (en)	1996-06-21	1998-04-21	Minnesota Mining And Manufacturing Company	Process for reparing imidazoquinolinamines
UA67760C2 (uk) *	1997-12-11	2004-07-15	Міннесота Майнінг Енд Мануфакчурінг Компані	Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6518280B2 (en)	1998-12-11	2003-02-11	3M Innovative Properties Company	Imidazonaphthyridines
US20020058674A1 (en)	1999-01-08	2002-05-16	Hedenstrom John C.	Systems and methods for treating a mucosal surface
EP1495758A3 (fr) *	1999-01-08	2005-04-13	3M Innovative Properties Company	Formulations et procédés utilisés pour le traitement des états pathologiques des muqueuses au moyen d'un modificateur de la réponse immunitaire
HU229441B1 (en) *	1999-01-08	2013-12-30	3M Innovative Properties Co	Formulations and methods for treating mucosal associated conditions with an immune response modifier
US6486168B1 (en)	1999-01-08	2002-11-26	3M Innovative Properties Company	Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6558951B1 (en) *	1999-02-11	2003-05-06	3M Innovative Properties Company	Maturation of dendritic cells with immune response modifying compounds
US6541485B1 (en)	1999-06-10	2003-04-01	3M Innovative Properties Company	Urea substituted imidazoquinolines
US6331539B1 (en)	1999-06-10	2001-12-18	3M Innovative Properties Company	Sulfonamide and sulfamide substituted imidazoquinolines
US6573273B1 (en)	1999-06-10	2003-06-03	3M Innovative Properties Company	Urea substituted imidazoquinolines
US6756382B2 (en) *	1999-06-10	2004-06-29	3M Innovative Properties Company	Amide substituted imidazoquinolines
US6916925B1 (en)	1999-11-05	2005-07-12	3M Innovative Properties Co.	Dye labeled imidazoquinoline compounds
US6376669B1 (en)	1999-11-05	2002-04-23	3M Innovative Properties Company	Dye labeled imidazoquinoline compounds
JP3436512B2 (ja) *	1999-12-28	2003-08-11	株式会社デンソー	アクセル装置
US6787342B2 (en) *	2000-02-16	2004-09-07	Merial Limited	Paste formulations
US6894060B2 (en) *	2000-03-30	2005-05-17	3M Innovative Properties Company	Method for the treatment of dermal lesions caused by envenomation
BR0112386A (pt) *	2000-06-22	2003-06-10	3M Innovative Properies Compan	Sistema e métodos para tratar uma superfìcie mucosal
UA81099C2 (en) *	2000-06-22	2007-12-10		System for treating a mucosal surface comprising an immune response modifier
DE10033853A1 (de) *	2000-07-12	2002-01-31	Hexal Ag	Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
JP2004520088A (ja)	2000-08-15	2004-07-08	サーモディックス，インコーポレイティド	薬剤混和マトリックス
US20020055517A1 (en) *	2000-09-15	2002-05-09	3M Innovative Properties Company	Methods for delaying recurrence of herpes virus symptoms
JP2002145777A (ja) *	2000-11-06	2002-05-22	Sumitomo Pharmaceut Co Ltd	アラキドン酸誘発皮膚疾患治療剤
US6664260B2 (en)	2000-12-08	2003-12-16	3M Innovative Properties Company	Heterocyclic ether substituted imidazoquinolines
US6545016B1 (en)	2000-12-08	2003-04-08	3M Innovative Properties Company	Amide substituted imidazopyridines
US6545017B1 (en)	2000-12-08	2003-04-08	3M Innovative Properties Company	Urea substituted imidazopyridines
US6677348B2 (en) *	2000-12-08	2004-01-13	3M Innovative Properties Company	Aryl ether substituted imidazoquinolines
US20020110840A1 (en) *	2000-12-08	2002-08-15	3M Innovative Properties Company	Screening method for identifying compounds that selectively induce interferon alpha
UA74852C2 (en)	2000-12-08	2006-02-15	3M Innovative Properties Co	Urea-substituted imidazoquinoline ethers
US6664264B2 (en) *	2000-12-08	2003-12-16	3M Innovative Properties Company	Thioether substituted imidazoquinolines
US6525064B1 (en)	2000-12-08	2003-02-25	3M Innovative Properties Company	Sulfonamido substituted imidazopyridines
EP1850850A4 (fr) *	2000-12-08	2011-06-15	3M Innovative Properties Co	Compositions et procedes pour l'apport cible d'agents modifiant la reaction immunitaire
US6660735B2 (en) *	2000-12-08	2003-12-09	3M Innovative Properties Company	Urea substituted imidazoquinoline ethers
US6677347B2 (en) *	2000-12-08	2004-01-13	3M Innovative Properties Company	Sulfonamido ether substituted imidazoquinolines
US6660747B2 (en) *	2000-12-08	2003-12-09	3M Innovative Properties Company	Amido ether substituted imidazoquinolines
US6664265B2 (en)	2000-12-08	2003-12-16	3M Innovative Properties Company	Amido ether substituted imidazoquinolines
US6667312B2 (en) *	2000-12-08	2003-12-23	3M Innovative Properties Company	Thioether substituted imidazoquinolines
US7226928B2 (en) *	2001-06-15	2007-06-05	3M Innovative Properties Company	Methods for the treatment of periodontal disease
US20030068375A1 (en)	2001-08-06	2003-04-10	Curtis Wright	Pharmaceutical formulation containing gelling agent
JP2005501550A (ja) *	2001-08-30	2005-01-20	スリーエムイノベイティブプロパティズカンパニー	免疫反応調整剤分子を用いた形質細胞様樹状細胞を成熟させる方法
EP1455700A4 (fr) *	2001-11-16	2007-02-14	3M Innovative Properties Co	Procedes et compositions lies a des composes irm et a des voies de recepteurs de type toll (tlr)
ES2312659T3 (es) *	2001-11-29	2009-03-01	3M Innovative Properties Company	Formulaciones farmaceuticas que comprenden un modificador de la respuesta inmune.
CA2365732A1 (fr) *	2001-12-20	2003-06-20	Ibm Canada Limited-Ibm Canada Limitee	Etalonnages
US6677349B1 (en) *	2001-12-21	2004-01-13	3M Innovative Properties Company	Sulfonamide and sulfamide substituted imidazoquinolines
HUE025145T2 (en) *	2002-02-22	2016-01-28	Meda Ab	A method for reducing and treating immunosuppression induced by ultraviolet B radiation
JP2005538057A (ja) *	2002-06-07	2005-12-15	スリーエムイノベイティブプロパティズカンパニー	エーテル置換イミダゾピリジン
US7700248B2 (en) *	2002-07-08	2010-04-20	Eastman Kodak Company	Organic charge transporting polymers including charge transport moieties and silane groups, and silsesquioxane compositions prepared therefrom
DK1545597T3 (da)	2002-08-15	2011-01-31	3M Innovative Properties Co	Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons
JP2006503068A (ja) *	2002-09-26	2006-01-26	スリーエムイノベイティブプロパティズカンパニー	１ｈ−イミダゾダイマー
AU2003287316A1 (en) *	2002-12-11	2004-06-30	3M Innovative Properties Company	Assays relating to toll-like receptor activity
WO2004053057A2 (fr) *	2002-12-11	2004-06-24	3M Innovative Properties Company	Systemes d'expression genetique et lignees cellulaires de recombinaison
CA2510375A1 (fr)	2002-12-20	2004-07-15	3M Innovative Properties Company	Imidazoquinoleines a substitution aryle/heteroaryle
EP2572714A1 (fr) *	2002-12-30	2013-03-27	3M Innovative Properties Company	Combinaisons immunostimulantes
JP2006517974A (ja) *	2003-02-13	2006-08-03	スリーエムイノベイティブプロパティズカンパニー	Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物
EP1599726A4 (fr) *	2003-02-27	2009-07-22	3M Innovative Properties Co	Modulation selective d'une activite biologique induite par le recepteur tlr
JP2006519866A (ja)	2003-03-04	2006-08-31	スリーエムイノベイティブプロパティズカンパニー	Ｕｖ誘発性の表皮の新形成の予防的治療
US7163947B2 (en) *	2003-03-07	2007-01-16	3M Innovative Properties Company	1-Amino 1H-imidazoquinolines
JP2006519877A (ja) *	2003-03-07	2006-08-31	スリーエムイノベイティブプロパティズカンパニー	１−アミノ１ｈ−イミダゾキノリン
AU2004220465A1 (en) *	2003-03-13	2004-09-23	3M Innovative Properties Company	Method of tattoo removal
WO2004080293A2 (fr) *	2003-03-13	2004-09-23	3M Innovative Properties Company	Methodes de diagnostic de lesions de la peau
KR20050109562A (ko) *	2003-03-13	2005-11-21	쓰리엠 이노베이티브 프로퍼티즈 컴파니	피부의 질을 개선시키는 방법
US20040192585A1 (en) *	2003-03-25	2004-09-30	3M Innovative Properties Company	Treatment for basal cell carcinoma
EP1615665A4 (fr) *	2003-04-10	2010-10-06	3M Innovative Properties Co	Administration de composes modificateurs de reaction immunitaire
US20040265351A1 (en) *	2003-04-10	2004-12-30	Miller Richard L.	Methods and compositions for enhancing immune response
WO2004096144A2 (fr) *	2003-04-28	2004-11-11	3M Innovative Properties Company	Compositions et methodes d'induction de recepteurs opoides
WO2004110991A2 (fr) *	2003-06-06	2004-12-23	3M Innovative Properties Company	PROCESSUS DE PREPARATION D'IMIDAZO[4,5-c]PYRIDINE-4-AMINES
AR044466A1 (es) *	2003-06-06	2005-09-14	3M Innovative Properties Co	Proceso para la preparacion de imidazo [4,5-c] piridin-4-aminas
US20080039533A1 (en) *	2003-07-31	2008-02-14	3M Innovative Properties Company	Bioactive Compositions Comprising Triazines
US8211906B1 (en)	2003-08-05	2012-07-03	Scherrer Lawrence C	Method of inhibiting growth of neoplastic cells and inhibiting infection by administering an immune enhancer drug
CN1852711A (zh) *	2003-08-05	2006-10-25	3M创新有限公司	使用免疫响应调节化合物的传染病预防
BRPI0413558A (pt)	2003-08-12	2006-10-17	3M Innovative Properties Co	compostos contendo imidazo substituìdo por hidroxilamina
US7799800B2 (en) *	2003-08-14	2010-09-21	3M Innovative Properties Company	Lipid-modified immune response modifiers
JP2007504145A (ja) *	2003-08-25	2007-03-01	スリーエムイノベイティブプロパティズカンパニー	免疫刺激性の組み合わせおよび治療
US8961477B2 (en)	2003-08-25	2015-02-24	3M Innovative Properties Company	Delivery of immune response modifier compounds
AU2004268625B2 (en)	2003-08-27	2011-03-31	3M Innovative Properties Company	Aryloxy and arylalkyleneoxy substituted imidazoquinolines
EP1663222A4 (fr) *	2003-09-02	2008-05-21	3M Innovative Properties Co	Methodes associees au traitement de pathologies des muqueuses
AU2004270201A1 (en) *	2003-09-05	2005-03-17	3M Innovative Properties Company	Treatment for CD5+ B cell lymphoma
EP1664342A4 (fr) *	2003-09-17	2007-12-26	3M Innovative Properties Co	Modulation selective de l'expression de genes tlr
US7544697B2 (en)	2003-10-03	2009-06-09	Coley Pharmaceutical Group, Inc.	Pyrazolopyridines and analogs thereof
KR20060120069A (ko)	2003-10-03	2006-11-24	쓰리엠 이노베이티브 프로퍼티즈 컴파니	피라졸로피리딘 및 그의 유사체
US20090075980A1 (en) *	2003-10-03	2009-03-19	Coley Pharmaceutical Group, Inc.	Pyrazolopyridines and Analogs Thereof
AR046046A1 (es)	2003-10-03	2005-11-23	3M Innovative Properties Co	Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas.
JP2007509987A (ja) *	2003-10-31	2007-04-19	スリーエムイノベイティブプロパティズカンパニー	免疫応答調節剤化合物による好中球活性化
CA2545825A1 (fr)	2003-11-14	2005-06-02	3M Innovative Properties Company	Composes d'un anneau d'imidazo substitue par hydroxylamine
EP1685129A4 (fr) *	2003-11-14	2008-10-22	3M Innovative Properties Co	Composes d'un anneau d'imidazo substitues par oxime
CA2547020C (fr)	2003-11-25	2014-03-25	3M Innovative Properties Company	Derives de 1h-imidazo[4,5-c]pyridine-4-amine en tant que compose modificateur de la reponse immunitaire
EP1686992A4 (fr) *	2003-11-25	2009-11-04	3M Innovative Properties Co	Hydroxylamine, et imidazoquinoleines, et imidazopyridines et imidazonaphtyridine substitues d'oxime
US20050226878A1 (en) *	2003-12-02	2005-10-13	3M Innovative Properties Company	Therapeutic combinations and methods including IRM compounds
US8940755B2 (en) *	2003-12-02	2015-01-27	3M Innovative Properties Company	Therapeutic combinations and methods including IRM compounds
US6943470B2 (en) *	2003-12-02	2005-09-13	Siemens Westinghouse Power Corporation	Air gap baffle assembly for gas-cooled turbine generator and method of installing
JP2007513170A (ja) *	2003-12-04	2007-05-24	スリーエムイノベイティブプロパティズカンパニー	スルホン置換イミダゾ環エーテル
JP2007517035A (ja)	2003-12-29	2007-06-28	スリーエムイノベイティブプロパティズカンパニー	アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン
JP2007530450A (ja) *	2003-12-29	2007-11-01	スリーエムイノベイティブプロパティズカンパニー	ピペラジン、［１，４］ジアゼパン、［１，４］ジアゾカン、および［１，５］ジアゾカン縮合イミダゾ環化合物
EP1699788A2 (fr)	2003-12-30	2006-09-13	3M Innovative Properties Company	Sulfonamides d'imidazoquinolinyle, d'imidazopyridinyle et d'imidazonaphtyridinyle
US20050239735A1 (en) *	2003-12-30	2005-10-27	3M Innovative Properties Company	Enhancement of immune responses
CA2559607C (fr)	2004-03-15	2013-02-19	3M Innovative Properties Company	Formulations modificatrices de reponse immunitaire et procedes correspondants
WO2005094531A2 (fr)	2004-03-24	2005-10-13	3M Innovative Properties Company	Imidazopyridines, imidazoquinolines, et imidazonaphthyridines a substitution amide
JP2007532572A (ja) *	2004-04-09	2007-11-15	スリーエムイノベイティブプロパティズカンパニー	免疫反応調整剤を送達させるための方法、組成物および調製物
MXPA06012451A (es) *	2004-04-28	2007-01-31	3M Innovative Properties Co	Composiciones y metodos para vacunacion por la mucosa.
US20050267145A1 (en) *	2004-05-28	2005-12-01	Merrill Bryon A	Treatment for lung cancer
WO2005123079A2 (fr) *	2004-06-14	2005-12-29	3M Innovative Properties Company	Imidazopyridines, imidazoquinolines et imidazonaphthyridines a substitution uree
US8017779B2 (en)	2004-06-15	2011-09-13	3M Innovative Properties Company	Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US8026366B2 (en)	2004-06-18	2011-09-27	3M Innovative Properties Company	Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006065280A2 (fr)	2004-06-18	2006-06-22	3M Innovative Properties Company	Composes a noyau imidazo a substitutif d'isoxazole, de dihydroisoxazole et d'oxadiazole
US8541438B2 (en)	2004-06-18	2013-09-24	3M Innovative Properties Company	Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006038923A2 (fr)	2004-06-18	2006-04-13	3M Innovative Properties Company	Imidazonaphthyridines substituees par aryle
US7884207B2 (en) *	2004-06-18	2011-02-08	3M Innovative Properties Company	Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US20070259881A1 (en) *	2004-06-18	2007-11-08	Dellaria Joseph F Jr	Substituted Imidazo Ring Systems and Methods
WO2006026470A2 (fr) *	2004-08-27	2006-03-09	3M Innovative Properties Company	Compositions immunostimulatrices contre le vih
US20090270443A1 (en) *	2004-09-02	2009-10-29	Doris Stoermer	1-amino imidazo-containing compounds and methods
EP1789042B1 (fr) *	2004-09-02	2012-05-02	3M Innovative Properties Company	Systemes cycliques 1-alcoxy 1h-imidazo et procedes associes
WO2006029115A2 (fr)	2004-09-02	2006-03-16	3M Innovative Properties Company	Systemes cycliques de 2-amino 1h-imidazo et procedes correspondants
US20080193468A1 (en) *	2004-09-08	2008-08-14	Children's Medical Center Corporation	Method for Stimulating the Immune Response of Newborns
EP1804583A4 (fr) *	2004-10-08	2009-05-20	3M Innovative Properties Co	Adjuvant pour vaccin a adn
EP1819364A4 (fr) *	2004-12-08	2010-12-29	3M Innovative Properties Co	Compositions, combinaisons immunomodulatrices et procedes associes
US8080560B2 (en) *	2004-12-17	2011-12-20	3M Innovative Properties Company	Immune response modifier formulations containing oleic acid and methods
EP1831221B1 (fr)	2004-12-30	2012-08-08	3M Innovative Properties Company	Composes chiraux 1,2 imidazo 4,5-c substitues a noyau fusionne
JP5543068B2 (ja)	2004-12-30	2014-07-09	スリーエムイノベイティブプロパティズカンパニー	キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
PL1830876T3 (pl)	2004-12-30	2015-09-30	Meda Ab	Zastosowanie imikwimodu do leczenia przerzutów do skóry wywodzących się od guza stanowiącego raka piersi
CA2592897A1 (fr) *	2004-12-30	2006-07-13	Takeda Pharmaceutical Company Limited	1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphtyridin-4-amine ethanesulfonate et 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphtyridin-4-amine methanesulfonate
US8436176B2 (en) *	2004-12-30	2013-05-07	Medicis Pharmaceutical Corporation	Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
AU2006210392A1 (en)	2005-02-04	2006-08-10	Coley Pharmaceutical Group, Inc.	Aqueous gel formulations containing immune response modifiers
US8378102B2 (en)	2005-02-09	2013-02-19	3M Innovative Properties Company	Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods
AU2006212765B2 (en) *	2005-02-09	2012-02-02	3M Innovative Properties Company	Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
EP1845988A2 (fr)	2005-02-11	2007-10-24	3M Innovative Properties Company	Imidazoquinolines et imidazonaphthyridines substituees
AU2006213746A1 (en)	2005-02-11	2006-08-17	Coley Pharmaceutical Group, Inc.	Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods
AU2006216686A1 (en)	2005-02-23	2006-08-31	Coley Pharmaceutical Group, Inc.	Method of preferentially inducing the biosynthesis of interferon
JP2008531567A (ja)	2005-02-23	2008-08-14	コーリーファーマシューティカルグループ，インコーポレイテッド	ヒドロキシアルキル置換イミダゾキノリン化合物および方法
EP1851224A2 (fr)	2005-02-23	2007-11-07	3M Innovative Properties Company	Imidazoquinolines a substitution hydroxyalkyle
EP1851220A2 (fr)	2005-02-23	2007-11-07	3M Innovative Properties Company	Imidazonaphthyridines a substitution hydroxyalkyle
JP2008533148A (ja)	2005-03-14	2008-08-21	スリーエムイノベイティブプロパティズカンパニー	光線性角化症の治療方法
EP1869043A2 (fr)	2005-04-01	2007-12-26	Coley Pharmaceutical Group, Inc.	Pyrazolopyridine-1,4-diamines et analogues associes
AU2006232375A1 (en)	2005-04-01	2006-10-12	Coley Pharmaceutical Group, Inc.	1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
CA2605808A1 (fr) *	2005-04-25	2006-11-02	3M Innovative Properties Company	Compositions immunostimulantes
ZA200803029B (en) *	2005-09-09	2009-02-25	Coley Pharm Group Inc	Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
EA200800782A1 (ru)	2005-09-09	2008-08-29	Коли Фармасьютикал Груп, Инк.	ПРОИЗВОДНЫЕ АМИДА И КАРБАМАТА N-{2-[4-АМИНО-2-(ЭТОКСИМЕТИЛ)-1Н-ИМИДАЗОЛО[4,5-c]ХИНОЛИН-1-IL]-1,1-ДИМЕТИЛЭТИЛ}МЕТАНСУЛЬФОНАМИДА И СПОСОБЫ
US8889154B2 (en)	2005-09-15	2014-11-18	Medicis Pharmaceutical Corporation	Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
KR20080083270A (ko)	2005-11-04	2008-09-17	콜레이 파마시티컬 그룹, 인코포레이티드	하이드록시 및 알콕시 치환된 1에이치 이미다조퀴놀린 및방법
WO2007079203A2 (fr) *	2005-12-28	2007-07-12	3M Innovative Properties Company	Traitement du lymphome t cutane
EP1988896A4 (fr)	2006-02-22	2011-07-27	3M Innovative Properties Co	Conjugués du modificateur de réponse immune
US8329721B2 (en)	2006-03-15	2012-12-11	3M Innovative Properties Company	Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
US7906506B2 (en)	2006-07-12	2011-03-15	3M Innovative Properties Company	Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
AU2007275815A1 (en) *	2006-07-18	2008-01-24	Wirra Ip Pty. Ltd.	Immune response modifier formulations
CA2659733A1 (fr) *	2006-07-31	2008-02-07	3M Innovative Properties Company	Compositions topiques sterilisees de 1 (2 methylpropyl) 1h imidazo[4,5 c]quinolin 4 amine
US8178539B2 (en)	2006-09-06	2012-05-15	3M Innovative Properties Company	Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
US20080149123A1 (en)	2006-12-22	2008-06-26	Mckay William D	Particulate material dispensing hairbrush with combination bristles
MX2009008935A (es)	2007-02-23	2009-11-02	Gilead Sciences Inc	Moduladores de las propiedades farmacocineticas de productos terapeuticos.
MX2010011963A (es)	2008-05-02	2010-12-06	Gilead Sciences Inc	Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
US20110033515A1 (en) *	2009-08-04	2011-02-10	Rst Implanted Cell Technology	Tissue contacting material
WO2011084725A1 (fr) *	2009-12-21	2011-07-14	3M Innovative Properties Company	Compositions de 1-hydroxynaphtalène-2-carboxylate de 4-amino-2-(éthoxyméthyl)-1-(2-hydroxy-2-méthylpropyl)-1h-imidazo[4,5-c]quinolin-5-ium et procédés correspondants
US9242980B2 (en)	2010-08-17	2016-01-26	3M Innovative Properties Company	Lipidated immune response modifier compound compositions, formulations, and methods
BR112013031039B1 (pt)	2011-06-03	2020-04-28	3M Innovative Properties Co	compostos de hidrazino 1h-imidazoquinolina-4-aminas, conjugados feitos destes compostos, composição e composição farmacêutica compreendendo ditos compostos e conjugados, usos dos mesmos e método de fabricação do conjugado
JP6460789B2 (ja)	2011-06-03	2019-01-30	スリーエムイノベイティブプロパティズカンパニー	ポリエチレングリコールセグメントを有するヘテロ２官能性リンカー及び該リンカーから調製された免疫反応調節複合体
US20130023736A1 (en)	2011-07-21	2013-01-24	Stanley Dale Harpstead	Systems for drug delivery and monitoring
WO2013162828A1 (fr)	2012-04-27	2013-10-31	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Utilisation d'oligonucléotides cpg co-formulés avec un antibiotique pour accélérer la cicatrisation des plaies
RU2737765C2 (ru)	2012-05-04	2020-12-02	Пфайзер Инк.	Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
CN113842362A (zh)	2012-11-14	2021-12-28	格雷斯公司	含有生物活性材料与无序无机氧化物的组合物
CN121243402A (zh)	2014-07-09	2026-01-02	博笛生物科技有限公司	用于治疗肿瘤的抗-pd-l1组合
WO2016036871A1 (fr) *	2014-09-02	2016-03-10	Epien Medical, Inc.	Formulation servant au traitement de plaies chroniques
US20170304411A1 (en) *	2014-10-24	2017-10-26	Hprd - Health Products Research And Development Lda	Topical formulation for treating skin or mucosal infections, preparation method and uses thereof
KR102619747B1 (ko)	2017-01-10	2023-12-29	넥타르 테라퓨틱스	Tlr 효현제 화합물의 다중-아암 중합체 컨쥬게이트 및 관련 면역 요법적 치료 방법
WO2019123178A1 (fr)	2017-12-20	2019-06-27	3M Innovative Properties Company	Composés imidazo [4,5-c]quinoléine à substitution amide ayant un groupe de liaison à chaîne ramifiée destinés à être utilisés en tant que modificateur de la réponse immunitaire
IL286137B2 (en)	2019-02-13	2025-09-01	DEBx Medical Holding BV	Preparations for removing dead or contaminated tissues from body surface injuries and the oral cavity
WO2020226889A1 (fr) *	2019-05-07	2020-11-12	Wellstat Therapeutics Corporation	Formulations d'uridine triacétate dans de la triacétine
US12605349B2 (en)	2024-09-05	2026-04-21	Orbus Therapeutics, Inc.	Methods of treating grade 3 astrocytoma

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA831186B (en) *	1982-03-22	1983-11-30	Upjohn Ltd	Gelled pge2/triacetin solutions
IL73534A (en) *	1983-11-18	1990-12-23	Riker Laboratories Inc	1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
CA1272953A (fr) *	1984-10-08	1990-08-21	Yuji Makino	Compose pharmaceutique pour usage externe contenant de la vitasmine d.sub.3 de type acitf
ATE74357T1 (de)	1986-07-14	1992-04-15	Sandoz Ag	5-hetero- oder -aryl-substituierte imidazo(2,1a>isochinoline.
US4788064A (en) *	1987-07-31	1988-11-29	Warner-Lambert Company	Transdermal delivery system
US4814173A (en) *	1987-09-08	1989-03-21	Warner-Lambert Company	Silicone elastomer transdermal matrix system
US5238944A (en) *	1988-12-15	1993-08-24	Riker Laboratories, Inc.	Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
IL92537A (en) *	1988-12-15	1994-04-12	Riker Laboratories Inc	Topical preparations and dermal systems containing 1-isobutyl-H1-imidazo [C-4,5] quinoline-4-amine
EP0385630B1 (fr) *	1989-02-27	1996-11-27	Riker Laboratories, Inc.	4-Amino-1H-imidazo(4,5-c)quinolines comme antiviraux
US5389640A (en) *	1991-03-01	1995-02-14	Minnesota Mining And Manufacturing Company	1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
DE69229114T2 (de) *	1991-03-01	1999-11-04	Minnesota Mining And Mfg. Co., Saint Paul	1,2-substituierte 1h-imidazo[4,5-c]chinolin-4-amine
DE4117249C2 (de) *	1991-05-27	1998-05-14	Christian Dr Stief	Linsidomin zur Behandlung erektiler Dysfunktionen

1996
- 1996-12-03 US US08/759,992 patent/US5939090A/en not_active Expired - Lifetime
1997
- 1997-12-01 DE DE69723721T patent/DE69723721T2/de not_active Expired - Lifetime
- 1997-12-01 NZ NZ335821A patent/NZ335821A/en not_active IP Right Cessation
- 1997-12-01 ES ES97950772T patent/ES2200206T3/es not_active Expired - Lifetime
- 1997-12-01 KR KR10-1999-7004821A patent/KR100503716B1/ko not_active Expired - Fee Related
- 1997-12-01 JP JP52574098A patent/JP4615633B2/ja not_active Expired - Fee Related
- 1997-12-01 AU AU53686/98A patent/AU723897B2/en not_active Ceased
- 1997-12-01 PT PT97950772T patent/PT942724E/pt unknown
- 1997-12-01 IL IL13006597A patent/IL130065A/en not_active IP Right Cessation
- 1997-12-01 HU HU0000568A patent/HU229599B1/hu not_active IP Right Cessation
- 1997-12-01 EP EP97950772A patent/EP0942724B1/fr not_active Expired - Lifetime
- 1997-12-01 WO PCT/US1997/021995 patent/WO1998024436A2/fr not_active Ceased
- 1997-12-01 BR BRPI9713677-8A patent/BR9713677B1/pt not_active IP Right Cessation
- 1997-12-01 DK DK97950772T patent/DK0942724T3/da active
- 1997-12-01 AT AT97950772T patent/ATE245422T1/de active
- 1997-12-01 CA CA002273094A patent/CA2273094C/fr not_active Expired - Fee Related
- 1997-12-01 CZ CZ0195599A patent/CZ301713B6/cs not_active IP Right Cessation
1999
- 1999-06-01 NO NO19992638A patent/NO325684B1/no not_active IP Right Cessation
- 1999-06-04 US US09/325,369 patent/US6365166B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
HU229599B1 (hu)	2014-02-28
US20020015715A1 (en)	2002-02-07
CZ195599A3 (cs)	1999-09-15
US6365166B2 (en)	2002-04-02
KR20000069233A (ko)	2000-11-25
EP0942724A2 (fr)	1999-09-22
NO992638L (no)	1999-07-16
PT942724E (pt)	2003-12-31
BR9713677B1 (pt)	2009-05-05
NO325684B1 (no)	2008-07-07
IL130065A0 (en)	2000-02-29
HUP0000568A3 (en)	2001-01-29
US5939090A (en)	1999-08-17
DE69723721D1 (de)	2003-08-28
NZ335821A (en)	2001-04-27
BR9713677A (pt)	2000-03-28
HUP0000568A2 (hu)	2000-10-28
WO1998024436A3 (fr)	1998-08-06
DE69723721T2 (de)	2004-04-15
AU5368698A (en)	1998-06-29
JP4615633B2 (ja)	2011-01-19
ATE245422T1 (de)	2003-08-15
DK0942724T3 (da)	2003-11-17
JP2001501968A (ja)	2001-02-13
NO992638D0 (no)	1999-06-01
CA2273094A1 (fr)	1998-06-11
EP0942724B1 (fr)	2003-07-23
CZ301713B6 (cs)	2010-06-02
KR100503716B1 (ko)	2005-07-26
WO1998024436A2 (fr)	1998-06-11
AU723897B2 (en)	2000-09-07
CA2273094C (fr)	2005-08-16
ES2200206T3 (es)	2004-03-01

Legal Events

Date	Code	Title
2004-11-24	FF	Patent granted
2005-02-20	KB	Patent renewed
2008-01-22	KB	Patent renewed
2011-11-30	KB	Patent renewed
2016-06-30	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
US5939090A (en)	1999-08-17	Gel formulations for topical drug delivery
EP0526561B1 (fr)	1996-04-03	Composition facilitant la penetration percutanee de medicaments
JP2671248B2 (ja)	1997-10-29	薬効または化粧効果成分の浸透性増進方法
US20030072814A1 (en)	2003-04-17	Topical pharmaceutical composition for the treatment of warts
CA1315692C (fr)	1993-04-06	Compositions pharmaceutiques topiques a action systemique
CA1179600A (fr)	1984-12-18	Preparation therapeutique pour les dermatoses
EP0662819B1 (fr)	1996-04-24	Emulsion pharmaceutique d'huile dans l'eau a action antivirale contenant de la 9-[(2-hydroxyethoxy)methyl]guanine (acyclovir) ou un sel ou ester de ladite substance
RU2152784C1 (ru)	2000-07-20	Трансдермальное введение противоэпилептических лекарственных препаратов
JPS63152311A (ja)	1988-06-24	徐放性口腔用製剤
JPS61268631A (ja)	1986-11-28	経皮吸収性を高めた皮膚外用剤
JPS59148718A (ja)	1984-08-25	ユビデカレノン組成物
RU2185807C1 (ru)	2002-07-27	Пролонгированные лекарственные формы местного действия, оказывающие активирующее влияние на иммунную систему
JP2831030B2 (ja)	1998-12-02	３’‐アジド‐３’デオキシチミジンを有効成分とする経皮投与製剤用組成物
JP4885856B2 (ja)	2012-02-29	局所クロモリン製剤
SHIGEYAMA et al.	1999	Mixed base of hydrophilic ointment and purified lanolin to improve the drug release rate and absorption of water of minocycline hydrochloride ointment for treatment of bedsores
KR0178796B1 (ko)	1999-03-20	외용산제
CA2060501A1 (fr)	1990-12-14	Suspension dans un liquide anhydrique a base d'huile pour la delivrance d'un medicament
KR20030000344A (ko)	2003-01-06	툴로부테롤을 함유하는 경피흡수용 패취제
Tabbara et al.	1989	Minocycline levels in tears of patients with active trachoma
JPH0320227A (ja)	1991-01-29	皮膚外用剤
HU200689B (en)	1990-08-28	Process for producing endermic pharmaceutical compositions comprising pyrazolo(1,5-a)pyridine derivatives as active ingredient
JPH11199473A (ja)	1999-07-27	貼付剤用膏体
JPH10139687A (ja)	1998-05-26	皮膚外用液剤
JP2954179B1 (ja)	1999-09-27	パップ剤
KR19980015057A (ko)	1998-05-25	클렌부테롤-함유 경피흡수용 패취제 및 그의 제조방법